Cutting Edge Product Quality

the confidence of beautiful teeth, for a lifetime…

Dual Rough Surface Technology

  • Macro roughness for accelerated osseointegration
  • State of the art surface treatment technology: Increase early bone to implant contact 
  • Increased secondary stability
  • Clinical Research data of i-Fix implant has shown excellent osseointegration studied by MicroCT and Histomorphometry 
  • Shortened healing period  



For Simplified assembly and confidence for component positioning 

  • The implant system has the advantage of having one prosthetic platform for all diameters
  • The implant abutment connection is an internal hex design which provides a rigid connection and stable biological seal
  • Emerging bevel conical connection
  • Precise fit and meticulous tolerances 
  • Platform switching incorporated in all connections in order to move the abutment-implant interface away from the bone-implant interface
  • 12°Morse taper creates an optimal seal against bacterial endotoxin leakage, while maintaining excellent retention

Variable thread design from coronal to apical part allows gradual bone condense

  • Buttress thread engineered for superior primary stability
  • Enhanced surface area in the ‘cortical bone’ region (top 1.5 mm) with micro threads for lower stress levels
  • Reduction of stresses in bone at both crestal and cancellous level



For maximum bone volume around implant for improved soft tissue support

  • Allows self‐tapping properties
  • Provides excellent primary stability
  • Rounded ends prevents injury to vital structures
  • Minimal instrumentation‐ all implants can be placed using the same kit


For accelerated and improved osseointegration process

  • Clinically proven Sand blasted, large grit, acid etched (SLA) surface
  • Macro and micro roughness for predictable osseointegration
  • SLA has proven clinical efficacy in early implant loading
  • DUAL rough surface

Overview of Pre‐Clinical Studies

A. Biocompatibility Studies: 

A series of biocompatibility tests as per ISO 10993 series have been conducted. The biocompatibility testing included the tests for Cytotoxicity, Sensitization, Irritation, Acute systemic toxicity, Sub‐acute & sub‐chronic toxicity, Genotoxicity and Implantation. In all of these tests, the implants were non‐reactive and produced no greater response than the negative control employed in each test system.

B. Animal Study:

In vivo animal study was conducted to evaluate safety, efficacy and overall product performance. Animal studies used Rabbit model for specimen implantation for 6 weeks and 12 weeks. The result demonstrated that no tissue necrosis or local infection were evident and the implant showed excellent osseointegration.

C. Clinical Study:

i‐Fix Implants have been comprehensively evaluated in an extensive clinical trial at M.A.I.D.S, New Delhi and have demonstrated excellent results.